-
Uncategorized2 months agoRegenerative Medicine: Promise, Hype, and What Actually Works
From stem cells to platelet-rich plasma, regenerative medicine is often positioned as the future of healthcare. But not all approaches deliver on that promise. As interest...
-
Uncategorized2 months agoDrugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes. Read More
-
Uncategorized2 months ago
AACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven Era
SAN DIEGO – At the American Association for Cancer Research (AACR) Annual Meeting 2026, the conversation around AI-driven cancer research has moved decisively past theory. Now...
-
Uncategorized2 months ago
Amneal inks $1.1B Kashiv buyout to pursue biosimilar market leadership
The takeover will give Amneal control of four facilities to manufacture biosimilars for a planned wave of launches in the coming years.
-
Uncategorized2 months agoOpinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
On Tuesday, Secretary of Defense Pete Hegseth announced that the men and women who defend our nation will be able to choose whether to be protected...
-
Uncategorized2 months agoSTAT+: CMS, FDA team up to fast-track reimbursement for breakthrough devices
Federal regulators on Thursday announced a new Medicare coverage pathway for devices deemed breakthroughs by the Food and Drug Administration. The program aims to address longstanding...
-
Uncategorized2 months ago
David Reese to retire from Amgen
David Reese to retire from Amgen
-
Uncategorized2 months ago
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality shine through his mute world.
-
Uncategorized2 months ago
Novel KIR‑CAR T Approach Shows Early Activity Against Solid Tumors
CAR T cell therapies have revolutionized outcomes for certain blood cancers, yet their impact on solid tumors has lagged. The field has long wrestled with T...
-
Uncategorized2 months ago
BBOT shakes up leadership as RAS competitors get more visibility
Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in...
